EGYBORT 2MG INJECTION contains Bortezomib which belongs to the group of medicines called Antineoplastic agents. It is used in adult patients alone or with pegylated liposomal doxorubicin/dexamethasone to treat progressive multiple myeloma when anticancer therapy or hematopoietic stem cell transplantation becomes unsuitable to treat the disease.
EGYBORT 2MG INJECTION is also used in adult patients with rituximab, cyclophosphamide, doxorubicin and prednisone to treat untreated mantle cell lymphoma when hematopoietic stem cell transplantation becomes unsuitable to treat the disease.
Multiple myeloma is a type of cancer that occurs in plasma cells (white blood cells) which are generally characterized by symptoms such as bone pain, nausea, constipation and loss of appetite. Mantle Cell Lymphoma is a rare form of cancer that affects the lymphatic system, generally characterized by symptoms such as loss of appetite, fever, nausea and/or vomiting.
Your doctor may advise you to do regular blood tests to check your blood counts before and during treatment with EGYBORT 2MG INJECTION. It is not recommended for use in patients with severe lung or heart disease.
EGYBORT 2MG INJECTION is not recommended for use in pregnant and breastfeeding women. EGYBORT 2MG INJECTION is also not indicated for use in children and adolescents (below 18 years of age).
The most common side effects of receiving EGYBORT 2MG INJECTION are dizziness, increased heartbeat, sweating, abnormal vision, paresthesia (burning or pickling sensation), muscle pain and headache. Inform your doctor if any of the symptoms worsen during or after treatment with EGYBORT 2MG INJECTION.